Tesamorelin calculator
This is a research reference, not a product for sale or a dosing recommendation. No amount is selected for Tesamorelin. A listed name does not mean it is supplied in a vial or should be injected.
About Tesamorelin
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), studied for its ability to stimulate the body’s growth-hormone axis. Unlike most research peptides, tesamorelin has an FDA-approved prescription formulation for reducing excess abdominal fat in adults with HIV-associated lipodystrophy; that specific indication does not make it a general weight-management drug. Its effects involve growth hormone and IGF-I signaling, and the approved use has defined limits in official labeling.
At a glance
- Class
- Synthetic GHRH analogue; tesamorelin is the active peptide in FDA-approved Egrifta formulations.
- Studied mechanism
- Activates pituitary GHRH signaling, increasing endogenous growth hormone and downstream IGF-I.
- Evidence context
- FDA-approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy, not as a general obesity treatment.
Blank arithmetic calculator
For independently verified inputs, concentration equals entered vial amount in mg divided by added liquid in mL. Entered requested mg divided by concentration gives mL; multiplying mL by the actual syringe markings per mL gives units. Enable JavaScript to use the calculator. This math does not establish that a compound is suitable for injection.
Common questions
Is tesamorelin an investigational peptide?
Tesamorelin is an approved prescription drug in specific Egrifta formulations for excess abdominal fat in adults with HIV-associated lipodystrophy. That approval is indication-specific and should not be generalized to other uses.
How does tesamorelin differ from growth hormone?
Tesamorelin is a GHRH analogue that signals the pituitary to release endogenous growth hormone; it is not growth hormone itself. Its downstream effects include changes in IGF-I.
Research & references
- DailyMed: EGRIFTA SV (tesamorelin) prescribing information
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension
Related compound pages
Read the math guides · Browse all compound names